Cargando…

P-075: HYDROXYUREA: EFFECTS ON TREATMENT OF CHILDREN WITH HEMOGLOBINOPATHY SC

Detalles Bibliográficos
Autores principales:	A., CAMPOS, M., PARK
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Poster Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426837/ http://dx.doi.org/10.1097/01.HS9.0000873188.20258.fa

Ejemplares similares

P135: THE CLINGEN HEMOGLOBINOPATHY VARIANT CURATION EXPERT PANEL
por: Coralea Stephanou, C, et al.
Publicado: (2022)

P075. Secondary headache due to bilateral dissection of vertebral arteries
por: Villella, Valeria, et al.
Publicado: (2015)

P-018: MILESTONES ALONG MY PERSONAL JOURNEY WITH HYDROXYUREA
por: A., SHAKIR
Publicado: (2022)

5612571 EARLIER PRENATAL DIAGNOSIS OF HEMOGLOBINOPATHIES BY CELOCENTESIS
por: Antonino Giambona, A.G., et al.
Publicado: (2023)

P075 Feasibility of 12 weeks melatonin supplementation in Mild Cognitive Impairment
por: Menczel Schrire, Z, et al.
Publicado: (2022)

P130: PROVIDING ADEQUATE HEALTHCARE TO PEOPLE WITH HEMOGLOBINOPATHIES DURING THE PANDEMIC (COVID-19)
por: Sophia Delicou, S, et al.
Publicado: (2022)

P-034: EFFECTS OF HYDROXYUREA ON SKELETAL MUSCLE MICROVASCULATURE OF MICE WITH SICKLE CELL DISEASE
por: M., RICCETTI, et al.
Publicado: (2022)

P1481: THE INTERNATIONAL HEMOGLOBINOPATHY RESEARCH NETWORK (INHERENT): AN INTERNATIONAL INITIATIVE TO STUDY THE ROLE OF GENETIC MODIFIERS IN HEMOGLOBINOPATHIES
por: Kountouris, P., et al.
Publicado: (2022)

P-047: PROSPECTIVE IDENTIFICATION OF VARIABLES AS OUTCOMES FOR TREATMENT (PIVOT): A PHASE II CLINICAL TRIAL OF HYDROXYUREA FOR CHILDREN AND ADULTS WITH HBSC DISEASE
por: L., SMART, et al.
Publicado: (2022)

P-048: INFLUENCE OF SEVEN GENETIC POLYMORPHISMS ON THE RESPONSE TO SICKLE CELL DISEASE THERAPY WITH HYDROXYUREA
por: O., FRANCO SANTOS, et al.
Publicado: (2022)

P075 Travel or cheers? Examining the drivers and mechanisms of home court advantage in the 2020/2021 NBA regular season
por: Leota, J, et al.
Publicado: (2021)

P-009: IDENTIFYING BARRIERS FOR PATIENTS WITH SICKLE CELL DISEASE TO ACCESS TREATMENT WITH HYDROXYUREA – A QUALITATIVE ANALYSIS OF THE SUPPLY CHAIN IN GHANA
por: S., GRAVEN, et al.
Publicado: (2022)

Study on Hydroxyurea Response in Hemoglobinopathies Patients Using Genetic Markers and Liquid Erythroid Cultures
por: Sclafani, Serena, et al.
Publicado: (2016)

P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG?
por: F., GALACTÉROS, et al.
Publicado: (2022)

P102: PLASMA FREE HEMOGLOBIN AND REACTIVE OXYGEN SPECIES IN SICKLE CELL ANAEMIA PATIENTS UNDER HYDROXYUREA AND GLUTAMINE THERAPY
por: Giannaki, A, et al.
Publicado: (2022)

P1425: SYSTEMATIC INVESTIGATION OF HYDROXYUREA TREATMENT EFFECT IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
por: Bhat, Varsha, et al.
Publicado: (2023)

P075: Emergence of carbapenem-resistant enterobacteriaceae in surgical and intensive care units of a hospital with low usage of carbapenem in Kano, North West Nigeria
por: Yusuf, I, et al.
Publicado: (2013)

P-017: POINT-OF-CARE DIAGNOSTIC FOR QUANTIFICATION OF FOETAL HAEMOGLOBIN (HB F) LEVELS IN MONITORING HYDROXYUREA THERAPY FOR CHILDREN WITH SICKLE CELL DISEASE (SCD) IN GHANA
por: C., SEGBEFIA, et al.
Publicado: (2022)

P-028: CIRCULATING CD34+CD235A+ CELL COUNT CORRELATES WITH LEVELS OF HBF IN SICKLE CELL ANEMIA PATIENTS UNDER HYDROXYUREA TREATMENT
por: J., MILHOMENS, et al.
Publicado: (2022)

P-039: ALTERNATIVE DOSING AND PREVENTION OF TRANSFUSIONS (ADAPT): A PROSPECTIVE TRIAL EVALUATING TRANSFUSION UTILIZATION AND THE FEASIBILITY OF PHARMACOKINETIC HYDROXYUREA DOSING IN CHILDREN WITH SICKLE CELL ANEMIA IN UGANDA
por: POWER-HAYS, A., et al.
Publicado: (2022)

P-007: HYDROXYUREA FOR THE MANAGEMENT OF SICKLE CELL DISEASE IN LOW- AND MIDDLE-INCOME COUNTRIES: A SYSTEMATIC REVIEW (2000–2022)
por: L., TSHILOLO, et al.
Publicado: (2022)

P075 Strategies to improve sleep disorder diagnosis and management in the workplace: Perspectives of future shift workers living with sleep disorders
por: Brown, B, et al.
Publicado: (2023)

P1484: THE DANISH SCREENING PROGRAM FOR HEMOGLOBINOPATHIES: A 16-YEAR REVIEW
por: Gravholt, Esther, et al.
Publicado: (2023)

P1474: MOLECURAL MECHANISM OF CHEMOTHERAPEUTIC HYDROXYUREA IS MEDIATED BY NOS2
por: Dragojević, T., et al.
Publicado: (2022)

Comparison of in-vitro and in-vivo response to fetal hemoglobin production and γ-mRNA expression by hydroxyurea in Hemoglobinopathies
por: Italia, Khushnooma, et al.
Publicado: (2013)

P075 COVID-19 vaccination uptake in patients with cystic fibrosis
por: Manning, D.-E., et al.
Publicado: (2022)

PI-07: THE INTERNATIONAL HEMOGLOBINOPATHY RESEARCH NETWORK (INHERENT): AN INTERNATIONAL INITIATVE TO STUDY THE ROLE OF GENETIC MODIFIERS IN HEMOGLOBINOPATHIES
por: P., KOUNTOURIS, et al.
Publicado: (2022)

P1550: NEW GENERATION EKTACYTOMETRY STUDY OF RED BLOOD CELLS RHEOLOGICAL PARAMETERS IN HEMOGLOBINOPATHIES
por: Krishnevskaya, E., et al.
Publicado: (2022)

5610178 SURVIVAL AND COMPLICATIONS IN PATIENTS WITH HEMOGLOBINOPATHIES: THE EXPERIENCE OF A SINGLE DEPARTMENT OF THALASSEMIA AND SICKLE DISEASE
por: Xydaki, X.A., et al.
Publicado: (2023)

P-042: POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS ANALYSIS OF HYDROXYUREA, IN ADULT PATIENTS WITH SICKLE CELL DISEASE (SCD) RECEIVING BOTH TABLETS OR CAPSULES FORMULATIONS, AND EVALUATION OF DISEASE MARKERS
por: P., BARTOLUCCI, et al.
Publicado: (2022)

AB075. The relationship between benign prostatic hyperplasia/lower urinary tract symptoms and mean platelet volume: the role of metabolic syndrome
por: Zhao, Sicong, et al.
Publicado: (2016)

Hydroxyurea reduces leukocyte interactions with the vessel wall in a haemolytic mouse model via a possible NO/cGMP-mediated effect
por: Almeida, Camila B, et al.
Publicado: (2013)

5573836 CLINICOHEMATOLOGICAL CHARACTERISTICS OF IRON DEFICIENCY ANEMIA AND HEMOGLOBINOPATHIES IN PAKISTAN;AN EXPERIENCE OF NON HOSPITAL BASED LABORATORY
por: Aisha Arshad, A.A., et al.
Publicado: (2023)

Most adults with severe HbSC disease are not treated with hydroxyurea
por: Ghunney, William Kwesi, et al.
Publicado: (2023)

5595849 THE GUT MICROBIOME AND HYDROXYUREA EFFECT ON SICKLE CELL DISEASE CHILDREN FROM ANGOLA
por: Brito, M., et al.
Publicado: (2023)

PI-03: THE EFFECT OF HYDROXYUREA IN THE GUT MICROBIOME OF ANGOLAN CHILDREN WITH SICKLE CELL DISEASE
por: M., DELGADINHO, et al.
Publicado: (2022)

P1046: TREATMENT COMPARISON OF HYDROXYUREA VS RUXOLITINIB IN ESSENTIAL THROMBOCYTHEMIA (ET): A MATCHED COHORT ANALYSIS
por: Grunwald, Michael, et al.
Publicado: (2023)

P1358: MINING THE GENOME FOR ERYTHROID SPECIFIC ENHANCERS TO OPTIMIZE GENE THERAPY VECTORS FOR BETA-HEMOGLOBINOPATHIES
por: Paschoudi, Kiriaki, et al.
Publicado: (2023)

P1370: A NOVEL GENE THERAPY VECTOR FOR BETA-HEMOGLOBINOPATHIES WITH A SELECTIVE EXPANSION CASSETTE
por: Kirtsou, Alexandra, et al.
Publicado: (2023)

P1437: ASSESSING THE ROLE OF MICRORNAS IN HYDROXYUREA -MEDIATED HBF INDUCTION IN HAEMOGLOBINOPATHIES PATIENTS
por: Kargutkar, Neha, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ve53a5pe2dhb0i1q4i09dell3d